

# Jürgen Jahnsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595317/publications.pdf>

Version: 2024-02-01

129  
papers

8,815  
citations

57758

44  
h-index

43889

91  
g-index

134  
all docs

134  
docs citations

134  
times ranked

8166  
citing authors

#	ARTICLE	IF	CITATIONS
1	Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2017, 389, 2304-2316.	13.7	666
2	Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 431-440.	1.5	628
3	Clinical Course in Crohn's Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1430-1438.	4.4	617
4	Incidence and Prevalence of Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis in a Norwegian Population. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 99-103.	1.5	457
5	Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. <i>Gastroenterology</i> , 1998, 115, 551-563.	1.3	430
6	Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. <i>Lancet, The</i> , 2002, 359, 1661-1665.	13.7	397
7	Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. <i>Digestion</i> , 1997, 58, 176-180.	2.3	333
8	C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. <i>Gut</i> , 2008, 57, 1518-1523.	12.1	331
9	Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.. <i>Gut</i> , 1997, 40, 313-319.	12.1	237
10	Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSEN) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.9	228
11	Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN) <i>Tj ETQq1 1 0.784314 rgBT /Overlo</i>	1.5	199
12	Health-related Quality of Life in Patients with Inflammatory Bowel Disease Measured with the Short Form-36: Psychometric Assessments and a Comparison with General Population Norms. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 909-918.	1.9	190
13	Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2111-2117.	1.9	178
14	Vitamin D Status, Parathyroid Hormone and Bone Mineral Density in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 192-199.	1.5	169
15	Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 402-412.	1.9	168
16	Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 151, 660-669.e4.	1.3	162
17	Body Composition in Patients With Inflammatory Bowel Disease: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2003, 98, 1556-1562.	0.4	128
18	Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 365-373.	1.5	126

#	ARTICLE	IF	CITATIONS
19	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e177-e187.	3.9	122
20	Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN Study). <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1037-1043.	1.5	111
21	Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 45-52.	3.0	100
22	A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. <i>New England Journal of Medicine</i> , 2021, 385, 35-45.	27.0	98
23	Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 858-863.	1.5	89
24	Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1037-1045.	1.6	87
25	Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. <i>Journal of Internal Medicine</i> , 2019, 285, 653-669.	6.0	87
26	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1744.	7.4	83
27	Tetramer-visualized gluten-specific CD4+ T cells in blood as a potential diagnostic marker for coeliac disease without oral gluten challenge. <i>United European Gastroenterology Journal</i> , 2014, 2, 268-278.	3.8	79
28	Vitamin D deficiency in inflammatory bowel disease: prevalence and predictors in a Norwegian outpatient population. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 100-106.	1.5	79
29	Bone mineral density in patients with inflammatory bowel disease: A population-based prospective two-year follow-up study. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 145-153.	1.5	78
30	Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2375.	7.4	78
31	Fecal calprotectin variability in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1091-1092.	1.9	65
32	Secondary Hyperparathyroidism, Vitamin D Sufficiency, and Serum Calcium 5 Years After Gastric Bypass and Duodenal Switch. <i>Obesity Surgery</i> , 2013, 23, 384-390.	2.1	62
33	Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease. <i>Gastroenterology</i> , 2019, 156, 1428-1439.e10.	1.3	61
34	Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression. <i>Gut</i> , 2002, 51, 372-378.	12.1	60
35	Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease — associations with disease phenotype, treatment, and outcome. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 37-49.	2.3	58
36	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <i>Drugs</i> , 2020, 80, 99-113.	10.9	58

#	ARTICLE	IF	CITATIONS
37	Systemic Inflammation in Preclinical Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 161, 1526-1539.e9.	1.3	58
38	Interferon- $\beta$ -Secreting T Cells Localize to the Epithelium in Coeliac Disease. <i>Scandinavian Journal of Immunology</i> , 2002, 56, 652-664.	2.7	57
39	Relationships between inflammatory bowel disease and perinatal factors: Both maternal and paternal disease are related to preterm birth of offspring. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 847-855.	1.9	56
40	Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: Ten-year results from the IBSEN study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 441-453.	1.3	55
41	The Association Between Water Supply and Inflammatory Bowel Disease Based on a 1990-1993 Cohort Study in Southeastern Norway. <i>American Journal of Epidemiology</i> , 2008, 168, 1065-1072.	3.4	53
42	Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 351-358.	1.5	52
43	Pediatric Inflammatory Bowel Disease in Southeastern Norway: A Five-Year Follow-Up Study. <i>Digestion</i> , 2004, 70, 226-230.	2.3	48
44	Predictive Value of Serologic Markers in a Population-based Norwegian Cohort with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 406-414.	1.9	48
45	Restricted VH/VL usage and limited mutations in gluten-specific IgA of coeliac disease lesion plasma cells. <i>Nature Communications</i> , 2014, 5, 4041.	12.8	46
46	Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 397-406.	3.7	46
47	Direct cloning and tetramer staining to measure the frequency of intestinal gluten-reactive T cells in celiac disease. <i>European Journal of Immunology</i> , 2013, 43, 2605-2612.	2.9	45
48	Density of CD163 <sup>+</sup> CD11c <sup>+</sup> Dendritic Cells Increases and CD103 <sup>+</sup> Dendritic Cells Decreases in the Coeliac Lesion. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 186-194.	2.7	44
49	Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. <i>Paediatric Drugs</i> , 2020, 22, 409-416.	3.1	41
50	Mortality and causes of death in Crohn's disease: results from 20...years of follow-up in the IBSEN study. <i>Gut</i> , 2014, 63, 771-775.	12.1	39
51	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 699-708.	1.3	36
52	Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1679-1687.	1.9	35
53	A role for CCL28/CCR3 in T-cell homing to the human upper airway mucosa. <i>Mucosal Immunology</i> , 2015, 8, 107-114.	6.0	34
54	The INSPIRE study: Do personality traits predict general quality of life (Short form-36) in distressed patients with ulcerative colitis and Crohn's disease?. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1505-1513.	1.5	33

#	ARTICLE	IF	CITATIONS
55	Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 92-99.	1.3	31
56	Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. <i>Journal of Rheumatology</i> , 2001, 28, 590-4.	2.0	31
57	Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. <i>Arthritis and Rheumatology</i> , 2022, 74, 1321-1332.	5.6	31
58	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017, 31, 223-237.	4.6	30
59	Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM) <i>TJ ETQq1 1 0.784314 rgBTj/Overlook</i>	4.3	30
60	Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 969-979.	1.3	29
61	Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1867-1874.	1.9	28
62	Experience with Biosimilar Infliximab (Remsima®) in Norway. <i>Digestive Diseases</i> , 2017, 35, 83-90.	1.9	28
63	Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 322-329.	3.2	27
64	Fatigue is not associated with vitamin D deficiency in inflammatory bowel disease patients. <i>World Journal of Gastroenterology</i> , 2018, 24, 3293-3301.	3.3	27
65	Validity, Reliability, and Responsiveness of the Brief Pain Inventory in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-10.	1.9	26
66	Occurrence of hepatotoxicity and elevated liver enzymes in a Crohn's disease patient treated with infliximab. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1584-1586.	1.9	25
67	Longevity, clonal relationship, and transcriptional program of celiac disease-specific plasma cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	25
68	Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 984-991.	1.9	24
69	Similar Responses of Intestinal T Cells From Untreated Children and Adults With Celiac Disease to Deamidated Gluten Epitopes. <i>Gastroenterology</i> , 2017, 153, 787-798.e4.	1.3	24
70	Simultaneous purification of DNA and RNA from microbiota in a single colonic mucosal biopsy. <i>BMC Research Notes</i> , 2016, 9, 328.	1.4	22
71	Ultrasound Measurements of Calcaneus for Estimation of Skeletal Status in Patients with Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 790-797.	1.5	20
72	Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery. <i>Clinical Endocrinology</i> , 2018, 88, 372-379.	2.4	20

#	ARTICLE	IF	CITATIONS
73	Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1146-1156.	1.5	20
74	Patients'™ perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey*. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1437-1442.	1.5	19
75	Plasmacytoid dendritic cells are scarcely represented in the human gut mucosa and are not recruited to the celiac lesion. <i>Mucosal Immunology</i> , 2013, 6, 985-992.	6.0	17
76	The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients. <i>Scientific Reports</i> , 2018, 8, 17278.	3.3	17
77	Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1255-1268.	1.3	17
78	Discontinuation of Infliximab Therapy in Patients with Crohn's™ Disease. , 2022, 1, .		17
79	Ranitidine Bismuth Citrate With Clarithromycin Given Twice Daily Effectively Eradicates <i>Helicobacter pylori</i> and Heals Duodenal Ulcers. <i>American Journal of Gastroenterology</i> , 1998, 93, 380-385.	0.4	16
80	Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1724-1733.	1.3	16
81	A high-affinity human TCR-like antibody detects celiac disease gluten peptide's™MHC complexes and inhibits T cell activation. <i>Science Immunology</i> , 2021, 6, .	11.9	15
82	Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	15
83	Mortality and Causes of Death in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 141-145.	1.9	14
84	Self-esteem in patients with inflammatory bowel disease. <i>Quality of Life Research</i> , 2020, 29, 1839-1846.	3.1	14
85	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's™ Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
86	Pain may be an important factor to consider in inflammatory bowel disease patients troubled by fatigue. <i>United European Gastroenterology Journal</i> , 2017, 5, 687-693.	3.8	13
87	Bowel Damage in Patients With Long-term Crohn's™ Disease, Assessed by Magnetic Resonance Enterography and the LÄ©mann Index. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 75-82.e5.	4.4	13
88	Determinants of optimal bowel function in ileal pouch-anal anastomosis '™ physiological differences contributing to pouch function. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 8-14.	1.5	13
89	On the immune response to barley in celiac disease: Biased and public T's™cell receptor usage to a barley unique and immunodominant gluten epitope. <i>European Journal of Immunology</i> , 2020, 50, 256-269.	2.9	13
90	The Impact of Spondyloarthritis and Joint Symptoms on Health-Related Quality of Life and Fatigue in IBD Patients. Results From a Population-Based Inception Cohort (20-Year Follow-up in the Ibsen Study). <i>Inflammatory Bowel Diseases</i> , 2020, 26, 114-124.	1.9	12

#	ARTICLE	IF	CITATIONS
91	Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial. <i>Journal of Internal Medicine</i> , 2022, 292, 477-491.	6.0	12
92	Attention deficit and hyperactivity disorder symptoms respond to gluten-free diet in patients with coeliac disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 571-576.	1.5	11
93	Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. <i>BioDrugs</i> , 2020, 34, 681-694.	4.6	10
94	Pathogenic T Cells in Celiac Disease Change Phenotype on Gluten Challenge: Implications for T-Cell-Directed Therapies. <i>Advanced Science</i> , 2021, 8, e2102778.	11.2	10
95	Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study. <i>Obesity Surgery</i> , 2020, 30, 3426-3434.	2.1	9
96	Pain Severity and Vitamin D Deficiency in IBD Patients. <i>Nutrients</i> , 2020, 12, 26.	4.1	8
97	AB0442...Long-term safety and efficacy of biosimilar infliximab (CT-P13) after switching from originator infliximab: results from the 26-week open label extension of a norwegian randomised trial. , 2018, , .		8
98	Treatment and outcome of gastrointestinal bleeding due to peptic ulcers and erosions " (BLUE study). <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 8-15.	1.5	8
99	OP0017...THERAPEUTIC DRUG MONITORING COMPARED TO STANDARD TREATMENT OF PATIENTS STARTING INFLIXIMAB THERAPY: RESULTS FROM A MULTICENTRE RANDOMISED TRIAL OF 400 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 12-12.	0.9	7
100	Phenotype-Based Isolation of Antigen-Specific CD4 <sup>+</sup> T Cells in Autoimmunity: A Study of Celiac Disease. <i>Advanced Science</i> , 2022, 9, e2104766.	11.2	7
101	OP022 Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S13-S13.	1.3	6
102	Assessment of Bowel Inflammation and Strictures by Magnetic Resonance Enterography in Long-term Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 607-614.	1.3	5
103	Gastrointestinal bleeding due to peptic ulcers and erosions " a prospective observational study (BLUE) Tj ETQq1 1 0.784314 rgBT / 1.5 5		
104	Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. <i>Clinical and Experimental Gastroenterology</i> , 2022, Volume 15, 5-25.	2.3	5
105	Photodynamic Effects with 5-Aminolevulinic Acid on Cytokines and Exosomes in Human Peripheral Blood Mononuclear Cells. <i>Biomedicines</i> , 2022, 10, 232.	3.2	4
106	P208 Chronic fatigue in patients with inflammatory bowel disease is associated with lower health-related quality of life, low self-esteem, increased anxiety and depression. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S204-S205.	1.3	2
107	Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. <i>World Journal of Gastroenterology</i> , 2021, 27, 2039-2053.	3.3	2
108	FRIO140...Individualised infliximab treatment: a treatment strategy based on therapeutic drug monitoring. , 2018, , .		2

#	ARTICLE	IF	CITATIONS
109	The multidimensional fatigue inventory (MFI-20): psychometrical testing in a Norwegian sample of inflammatory bowel disease (IBD) patients. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-7.	1.5	2
110	OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i010-i010.	1.3	2
111	THU0354â€¦Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the randomized nor-switch-study: explorative analysis in SPA patients. , 2017, , .		1
112	Efficacy of infliximab biosimilars in patients with Crohn's disease â€œ Authors' reply. <i>Lancet</i> , The, 2017, 390, 2436.	13.7	1
113	FR10182â€¦Disease worsening and safety in patients switching from originator infliximab to biosimilar infliximab (CT-P13) in the nor-switch study: explorative analysis of RA patients. , 2017, , .		1
114	Editorial: awareness and prevention of intravenous ironâ€œinduced hypophosphataemia. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 610-611.	3.7	1
115	Editorial: improving precision of iron deficiency diagnosis in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 400-400.	3.7	1
116	P696 Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases â€œ secondary analyses from a randomised clinical trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i594-i595.	1.3	1
117	P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i537-i538.	1.3	1
118	Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseasesâ€œReply. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1506.	7.4	1
119	THU0700â€œImmunogenicity in patients switching from stable originator infliximab treatment to CT-P13: analyses across six diseases from the 52-week randomized nor-switch study. , 2017, , .		0
120	P061 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease â€œ IBD Character. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S108-S108.	1.3	0
121	P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S483-S484.	1.3	0
122	P250 Use of complementary and alternative medicine is associated with chronic fatigue and lower health-related quality of life in patients with inflammatory bowel disease 20 years after diagnosis: results from the IBSEN study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S221-S222.	1.3	0
123	P723 Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S482-S483.	1.3	0
124	OP0301â€œ...RISK FACTORS FOR ANTI-INFLIXIMAB ANTIBODY FORMATION: RESULTS FROM THE RANDOMISED CONTROLLED NOR-DRUM A TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 185.2-185.	0.9	0
125	P636 Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i555-i555.	1.3	0
126	DOP73 A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohnâ€™s Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i116-i117.	1.3	0



#	ARTICLE	IF	CITATIONS
127	P467 Therapeutic drug monitoring of biologics in Inflammatory Bowel Disease: Nordic survey on implementation and barriers in clinical practice. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i441-i441.	1.3	0
128	Duodenal ulcer healing rates in a one-year follow-up study with ranitidine bismuth citrate and antibiotics. <i>Hepato-Gastroenterology</i> , 2001, 48, 1641-7.	0.5	0
129	Abstract OT2-19-01: Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB study. <i>Cancer Research</i> , 2022, 82, OT2-19-01-OT2-19-01.	0.9	0